IMPACT BIOMEDICAL INC
IBONYSE AMERICANTrading Snapshot
- Day Range
- $5.54 – $5.70
- 52-Week Range
- $4.67 – $10.51
- Volume
- $1.66B
- Avg Volume
- $1.16B
- Shares Outstanding
- 8.5M
- Next Earnings
- Nov 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $32,000
- Last Q Revenue
- $3,000
- P/E Ratio
- -4.5
- P/S Ratio
- 1367.0x
- EPS (TTM)
- $0.09
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +174.1%
Why Investors Own IBO
- ✓High-growth profile — revenue up -9.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 64% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
IMPACT BIOMEDICAL INC
IBO
StockOtter · stockotter.spaceAbout IMPACT BIOMEDICAL INC
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited)
HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (NYSE: IBO) (the “Company” or “Impact”) announced that a Form F-4 registration statement (the “Registration Statement”) was filed with the U.S. Securitie
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “Company” or “
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley's Ltd.
HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (the “Company”) today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's issued and outstand